Can-Fite BioPharma Ltd. (NYSE:CANF) tinted gains of +4.2% (+0.05 points) to US$1.24. The volume of 0.17 Million shares climbed down over an trading activity of 222.05 Million shares. EPS ratio determined by looking at last 12 month figures is -0.3. Over the same time span, the stock marked US$2.75 as its best level and the lowest price reached was US$1.12. The corporation has a market cap of US$43.06 Million.
Can-Fite BioPharma Ltd. (NYSE:CANF)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at 0 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 19.57 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.
Cardlytics, Inc. (NASDAQ:CDLX) is worth US$443.98 Million and has recently risen 4.16% to US$22.78. The latest exchange of 0.09 Million shares is below its average trading activity of 146.52 Million shares. The day began at US$22.86 but the price moved to US$22.78 at one point during the trading and finally capitulating to a session high of US$22.86. The stock tapped a 52-week high of US$25.71 while the mean 12-month price target for the shares is US$26.5.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 7.35, and a price to sales ratio of 3.26. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 47.2%, it carries an earnings per share ratio of -2.17.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 5 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.